• À propos de nous
  • Équipe
  • Expertise
    • Secteurs
        • Technologie, Médias et Communications (TMC)
        • Fortune Privée
        • Immobilier, Infrastructure et Énergie
        • Sciences de la vie et Santé
        • Aérospatial et défense
        • Automobile et mobilité
        • Services aux entreprises et services professionnels
        • Industrie chimique
        • Droit de la consommation
        • Institutions financières et assurance
        • Hôtels et loisirs
        • Logistique et transport
        • Industrie
        • Droit public et Education
    • Compétences
        • Artificial intelligence
        • Banque et Finance
        • Droit des marques et publicité
        • Contrats commerciaux et de consommation
        • Concurrence, UE & commerce
        • Droit d’auteur et médias
        • Criminalité d’entreprise et conformité
        • Fusions et acquisitions d’entreprises et marchés financiers internationaux
        • Données et cybersécurité
        • Résolution des litiges
        • Droit social, pensions et mobilité
        • Planification environnementale et réglementation
        • Environmental, social & governance (ESG)
        • Intellectual property
        • Technologies de l'information
        • Brevets et innovation
        • Clients privés
        • Capital investissement
        • Projets Internationaux, Énergie & Infrastructure
        • Immobilier et construction
        • Regulation
        • Restructuration et insolvabilité
        • Fiscalité
        • Capital-risque
  • Bureaux
    • Europe
        • Pays
        • Autriche
        • Belgique
        • République tchèque
        • France
        • Allemagne
        • Hongrie
        • Italy
        • Pays-Bas
        • Pologne
        • Portugal
        • République d'Irlande
        • Slovaquie
        • Spain
        • Royaume-Uni
        • Ukraine
          Groupes et régions
        • CEE Turkish Desk
        • Groupe franco-allemand
        • Nos bureaux
    • Moyen-Orient et Afrique
        • Pays
        • Moyen-Orient
        • EAU
          Groupe
        • Groupe Afrique
        • Groupe Israël
        • Nos bureaux
    • Amérique
        • Pays
        • Latin America
        • Etats-Unis
          Groupe
        • Groupe Brésil
        • Nos bureaux
    • Asie
        • Pays
        • Asie
        • Chine
        • Corée du Sud
          Groupe
        • Groupe Inde
        • Groupe Japon
        • Nos bureaux
  • Publications & événements
    • Publications
        • Sujets d’actualités
        • Artificial intelligence
        • Data Centre Expertise
        • The EU Whistleblower Directive
        • German Supply Chain Act
        • Unified Patent Court
          Content hub
        • Global Data Hub
        • Interface: tech, IP and media law
        • Podcasts
        • Synapse
        • Parcourir les publications
    • Événements
        • En ligne
        • En présentiel
        • Browse all events
    • Actualités
        • Centre de médias
        • Points forts du travail
        • Actualités du cabinet
        • Voir tout
  • Carrières
  • FR
    • English
    • 中文(简体)
    • Français
    • Deutsch
  • Accueil
  • Équipe
  • Ross McNaughton
Ross McNaughton
Ross McNaughton

Ross McNaughton

Associé

  • Cambridge Royaume-Uni
+44 1223 446 443
vCard
Écrire Call me
Prix à l'honneur

Chambers and Partners UK 2026

Corporate/M&A: £5 million and above - Band 3: "Ross is a smart, pragmatic and knowledgeable lawyer with extensive life sciences connections. He is very available, easy to talk to and accommodating, and he gets the science." "Ross is very well known locally for being a strong technical lawyer with a good network and life sciences expertise."

Scroll to featured award

Ross is a partner in the Corporate and Life Sciences team, based in our Cambridge office.

Ross is a lead partner within the firm's Tier 1-ranked Biotechnology practice in Cambridge. His practice involves helping life sciences and technology companies as they progress through their life cycle in all aspects of their growth, capital raising and international expansion. As a sector specialist, Ross focuses on biotech, medical devices and diagnostics within Life Sciences, and with the Tech sector supports companies operating in the capital intensive deep tech space, including quantum computing, artificial intelligence, advanced materials, as well as web3.

Ross has extensive experience of a variety of venture and growth financing, public capital raisings, mergers and acquisitions and general corporate advice. Ross was based out of San Francisco, CA in 2018 – 19 and as a result, he has a particular expertise in transactions with a transatlantic component.

Expertise

Services et Groupes

Fusions et acquisitions d’entreprises et marchés financiers internationaux
Capital-risque
Artificial intelligence
M&A

Secteurs

Sciences de la vie et Santé
Technologie, Médias et Communications (TMC)
Cryptoactifs, blockchain et technologie des registres distribués (DLT) et projets Web 3.0
Apprentissage automatique

CV

Since 2020 Partner, Taylor Wessing LLP
2015 - 2020 Partner, Penningtons Manches Cooper LLP, Cambridge
2010 - 2015 Partner, Paul Hastings LLP, London
2002 - 2009 Lawyer, Herbert Smith
2018 Admitted as a foreign legal consultant, state bar of California
2004 Admitted as a lawyer, England and Wales
2001 LPC and Post Graduate Degree in Law, Nottingham Law School

Carrière

Since 2020 Partner, Taylor Wessing LLP
2015 - 2020 Partner, Penningtons Manches Cooper LLP, Cambridge
2010 - 2015 Partner, Paul Hastings LLP, London
2002 - 2009 Lawyer, Herbert Smith

Formation

2018 Admitted as a foreign legal consultant, state bar of California
2004 Admitted as a lawyer, England and Wales
2001 LPC and Post Graduate Degree in Law, Nottingham Law School

Langues étrangères

English

Prix et distinctions

Chambers and Partners UK 2026

Featured

Corporate/M&A: £5 million and above - Band 3: "Ross is a smart, pragmatic and knowledgeable lawyer with extensive life sciences connections. He is very available, easy to talk to and accommodating, and he gets the science." "Ross is very well known locally for being a strong technical lawyer with a good network and life sciences expertise."

Legal 500 UK 2026

Leading partner in the venture capital, biotechnology and corporate and commercial: Cambridge categories.

Legal 500 UK 2025

Leading partner

Legal 500 UK 2025

Leading partner

Leading partner

Corporate/M&A (mid-market and private equity) - Band 3: Ross McNaughton heads up the Cambridge corporate department at Taylor Wessing and represents a variety of technology and pharmaceutical clients in complex acquisitions. He also has strong expertise in financing matters. "Ross McNaughton has strong knowledge and sector experience."

‘A strength of Taylor Wessing is the depth of knowledge and expertise across different legal areas, and we were able to access this on a particularly complex transaction under the truly excellent leadership of Ross McNaughton.’ ‘Ross McNaughton and Adrian Toutoungi are our go-to partner specialists.’

Venture capital

Corporate and commercial - Cambridge (Leading individual): "Ross McNaughton was a key negotiating ally in our dealings with both investors and potential acquirers. He was able to lead complex and difficult interactions with third parties in a pragmatic and ultimately successful manner." "Ross McNaughton performed superbly during deal negotiations. His tenacity and ability to direct a legal team is commendable."

Biotechnology

Recognised as a notable practitioner

Venture capital

Experience

Advising on Draig Therapeutics' US$140 million series A financing

We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.

Press release
Ross McNaughton
Elinor Picton
Oli Denne
Helen Farr
Adrian Toutoungi
Charlie Adams
Nicholas Vollers
Ed Chapman

Blue Earth Therapeutics on the closing of US$76.5 million Series A funding

We have advised Blue Earth Therapeutics and its management on the closing of US$76.5 million Series A funding. The new funding comes from a broad spectrum of experienced biotech investors and enables Blue Earth Therapeutics to further advance its clinical stage prostate-specific membrane antigen-targeted radioligand therapies.

Press release
Ross McNaughton
Bella Thornton-Clark

Healx raises $47 million in its Series C funding

Advised Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases based in Cambridge UK, on its $47 million Series C funding. The funding was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s largest venture capital firms, with participation from new and existing investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners.

Press release
Ross McNaughton
Oli Denne

Advising gene therapy company AlveoGene on its complex spinout and launch investment

We have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.

Press release
Ross McNaughton
Bella Thornton-Clark

Advising on transformational life sciences combinations and cross-over rounds

Ross was the lead partner on the transformational roll-up and $250 million cross-over financing of Centessa Pharmaceuticals, representing eight cutting-edge UK and European biotech companies on their participation in a newly established holding company focused on the development of innovative new treatments. Ross was also the lead partner on the combination of three New Science Ventures-backed companies under Ventyx Biosciences Inc in the context of its concurrent $114 million financing led by venBio Partners.

Ross McNaughton

Acting on venture growth rounds for leading life sciences and tech businesses

Ross constantly acts for leading growth companies and investors on their funding rounds, including recently Cambridge Epigenetix on its $88 million series D funding round led by Temasek, Envelop Risk on its $130 million round led by SoftBank, and Oxbotica on its $47 million series B investment.

Ross McNaughton

Actualités et publications récentes

View Ross's insights
Cliquer ici pour en savoir plus
Fusions et acquisitions d’entreprises et marchés financiers internationaux

Advising on Sona's US$45 million Series B funding

8 avril 2026

par plusieurs auteurs

Glass.Mapper.Sc.Fields.Image?.Alt
Sciences de la vie et Santé

Advising on Tropic Biosciences' US$105 million Series C financing

25 mars 2026

par plusieurs auteurs

Cliquer ici pour en savoir plus
Glass.Mapper.Sc.Fields.Image?.Alt
Fusions et acquisitions d’entreprises et marchés financiers internationaux

Advising Lingotto on its extended Series A funding into Optalysys to US$60 million

6 février 2026

par plusieurs auteurs

Cliquer ici pour en savoir plus
View Ross's insights

Related news & insights

Fusions et acquisitions d’entreprises et marchés financiers internationaux

Advising Eurofins on the sale of its electrical and electronic testing business for EUR575 million

14 avril 2026

par Paul Thorpe et Jack Coventry

Cliquer ici pour en savoir plus

Taylor Wessing strengthens Corporate/M&A practice with Equity Partner Jan Hückel

1 avril 2026

par plusieurs auteurs

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

Request for a Preliminary Ruling by Federal Court of Justice on the Prohibition of Advertising for Remote Medical Treatments under Section 9 HWG

31 mars 2026
Briefing

par Dr. Daniel Tietjen et Daniel Dietrich

Cliquer ici pour en savoir plus
Search Result leaves
Environmental, social & governance (ESG)

Carbon Border Adjustment Mechanism (CBAM): From Reporting to Real Financial Impact

31 mars 2026

par Jan Rataj

Cliquer ici pour en savoir plus
Environmental, social & governance (ESG)

Sustainability Stories: Notpla

30 mars 2026
Briefing

par Ian Moore

Cliquer ici pour en savoir plus

EU Inc. – The 28th Regime: How the European Commission intends to revolutionise the formation of companies

27 mars 2026
In-depth analysis

par Philipp Hoegl et Alexander Schmalenberger, LL.B.

Cliquer ici pour en savoir plus
Droit de la consommation

Consumer and Retail in the News

27 mars 2026
Quick read

par plusieurs auteurs

Cliquer ici pour en savoir plus
Technologie, Médias et Communications (TMC)

Prediction Markets in Germany and Europe: Legal Status, Risks, and Opportunities

26 mars 2026
Briefing

par Dr. Fabian Masurat, CIPP/E

Cliquer ici pour en savoir plus
Fusions et acquisitions d’entreprises et marchés financiers internationaux

Investing in the German Audit and Tax Advisory Market – Opportunity Amid Regulatory Debate

26 mars 2026
Briefing

par plusieurs auteurs

Cliquer ici pour en savoir plus
Fusions et acquisitions d’entreprises et marchés financiers internationaux

More Than Share and Asset Deals: Innovative Transaction Structures for MedTech Companies

25 mars 2026
Briefing

par Christopher Peine

Cliquer ici pour en savoir plus
View all insights

Autres avocats qui pourraient vous intéresser

Royaume-Uni
Global
Mark Barron

Mark Barron

Associé

Londres
San Francisco
+44 20 7300 4241
Écrire
Consulter le profil complet

Dillan Madhani

Collaborateur

Londres
+44 20 7300 7000
Écrire
Consulter le profil complet

Henry Priestley

Associé

Londres
+44 20 7300 7000
Écrire
Consulter le profil complet

Chris Cowley

Associé

Londres
+44 20 7300 7189
Écrire
Consulter le profil complet

Ben Eaves

Collaborateur

Londres
+44 20 7300 7000
Écrire
Consulter le profil complet
Daniel Hirschfield

Daniel Hirschfield

Senior Counsel – Knowledge

Londres
+44 20 7300 7000
Écrire
Consulter le profil complet
James Goold

James Goold

Associé

Londres
+44 20 7300 4207
Écrire
Consulter le profil complet

Edward Waldron

Associé

Londres
+44 (0)20 7300 4968
Écrire
Consulter le profil complet

Anneka Dalton

Associé

Londres
+44 020 3077 7360
Écrire
Consulter le profil complet
Elinor Picton

Elinor Picton

Associé

Londres
+44 20 7300 4961
Écrire
Consulter le profil complet
Full team
Tabeling-Julie-

Julie Tabeling

Counsel

Paris
+33 1 72 74 03 33
Écrire
Consulter le profil complet

Dr. Gregor Schmid, LL.M. (Cambridge)

Associé

Berlin
+49 30 885636 0
Écrire
Consulter le profil complet
Alexander R. Roth

Alexander R. Roth, M.Jur. (Oxford)

Associé

San Francisco
New York
+1 650 666 8400
Écrire
Consulter le profil complet

Dr. Christian Frank, Licencié en droit (Paris II / Panthéon-Assas)

Associé

Munich
+49 89 21038 0
Écrire
Consulter le profil complet

Dr. Nicolai Wiegand, LL.M. (NYU)

Associé

Munich
+49 89 21038 0
Écrire
Consulter le profil complet
David Bates

David Bates

Associé

San Francisco
+1 650 772 5400
Écrire
Consulter le profil complet

Bella Thornton-Clark

Collaborateur senior

Londres
San Francisco
+44 20 7300 7000
Écrire
Consulter le profil complet

Rachel McCausland

Collaborateur senior

Dublin
+353 86 457 4042
Écrire
Consulter le profil complet
Clare Reynolds

Clare Reynolds

Associé

Londres
+44 207 300 7074
Écrire
Consulter le profil complet

Daniel Sterling

Collaborateur senior

Londres
+44 20 7300 7000
Écrire
Consulter le profil complet
Full team

Rendez-vous à

Voir tous les événements
Abonnez-vous à nos dernières actualités
  • À propos de nous
  • Campaigns and online tools
  • Actualités
  • Équipe
  • Expertise
  • Bureaux
  • Publications
  • Événements
  • Communiqués de Presse
  • Contact
  • Carrières
  • Alumni
  • Politique de Confidentialité
  • Politique en matière de confidentialité et de cookies
  • Informations légales et réglementaires
  • Informations réglementaires sur les coûts
  • Procédure de plainte pour les clients
  • Conditions d’utilisation
  • Anti-slavery statement
  • Environnement
  • Emails frauduleux

© Taylor Wessing